Khurram Rana, PharmD

Sr. Director
Innoviva Specialty Therapeutics

Disclosure(s): Innoviva Specialty Therapeutics: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-443) Population Pharmacokinetics (PPK) Analysis of Eravacycline (ERV) to Support Dose Selection for a Trial in Pediatric Patients Aged 8 to Less Than 18 Years with Complicated Intra-Abdominal Infection (cIAI)
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET